Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The company is headquartered in Boston, Massachusetts and currently employs 200 full-time employees. The company went IPO on 2021-02-02. The firm is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases directly. Its products include reSET and reSET-O. The firm's reSET product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Company’s pipeline consists of product candidates in psychiatry, neurology, and outside-of-central nervous system therapeutic areas. The firm has built a portfolio of PDT product candidates that is primarily focused on psychiatric conditions.

Industry: Services-Health Services Peers: Babylon Holdings Ltd CareCloud Inc TruBridge Inc Forian Inc. UpHealth, Inc. OptimizeRx Corp Tabula Rasa HealthCare, Inc. Akili, Inc.